Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis

Journal of Clinical Psychiatry

Volumn 61, Issue 12, 2000, Pages 933-941

  Brook, S ^a   Lucey, J V ^a   Gunn, K P ^a  

^a Sterkfontein Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LORAZEPAM; QUETIAPINE; RISPERIDONE; TEMAZEPAM; ZIPRASIDONE;

ACUTE PSYCHOSIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034531178     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n1208     Document Type: Article

References (38)

1. Parenteral treatment of acute psychotic patients with agitation: A review
2. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind emergency department study
3. A double-blind, randomized clinical trial of rapid tranquilization with IM clonazepam and LM haloperidol in agitated psychotic patients with manic symptoms
4. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting
5. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for the control of psychotic agitation
6. Parenteral lorazepam versus parenteral halopefidol for the control of psychotic disruptive behavior
7. Haloperidol and lorazepam combined: Clinical effects and drug plasma levels m the treatment of acute schizophrenic psychosis
8. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior
9. A prospective, randomised, doubleblind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients
10. Rapid tranquilization of the violent patient
11. Sedation in acute and chronic agitation
12. Subjective experiences of schizophrenic Patients treated with antipsychotic medication
13. Current concepts in the pharmacotherapy of acute psychosis
14. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebocontrolled trial
15. Ziprasidone 40 and 120 rag/day in the acute exacerbation of schizophrenia and schizoaffecfive disorder: A 4-week placebo-controlled trial
16. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
17. Ziprasidone (CP-88 059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
18. The novel antipsychotic ziprasidone has a unique human receptor binding profile comped with other agents
19. An exploratory, halopendol-controlled, dose-finding study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder
20. Anxiolytic effects of ziprasidone compared with diazepam and placebo prior to dental surgery
21. The tolerability and efficacy of intramuscular ziprasidone
22. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised
23. Anchoring the BPRS: An aid to improved reliability
24. A rating scale for extrapyramidal side-effects
25. A rating scale for drug-induced akathisia
26. Intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation
27. Remoxipride in acute psychosis: Intramuscular followed by oral treatment compared to haloperidol, a double-blind, multicenter trial
28. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis
29. A comparison of intramuscular (IM) ziprasidone with IM haloperidol
30. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent ziprasidone
31. Antipsychotic agents: A review
32. Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine
33. Use of benzodiazepines to control disruptive behavior in inpatients
34. New atypical antipsychotic medications
35. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients
36. Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia